85 related articles for article (PubMed ID: 11015998)
1. [Significance of interferon alpha therapy for advanced renal cell carcinoma. Fukushima Renal Cancer Study Group].
Ogihara M; Aikawa K; Suzuki T; Yanagida T; Kushida N; Yamaguchi O; Shiraiwa Y; Kumakawa K; Koseki K; Ichijo S; Date T; Kurosu S; Takeuchi M; Yokoyama J; Murakami F; Itoh K; Noguchi M
Gan To Kagaku Ryoho; 2000 Sep; 27(10):1533-9. PubMed ID: 11015998
[TBL] [Abstract][Full Text] [Related]
2. Multi-modal treatment of primarily using continuous subcutaneous interferon-alpha injection in combination with surgery and/or radiotherapy.
Maruoka M; Fujimura M; Kawamura K; Suzuki S; Hamano M; Nishikawa Y; Nagayama T
Int J Urol; 2005 May; 12(5):442-8. PubMed ID: 15948742
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous administration of interferon alpha and gamma in patients with metastatic renal cell carcinoma.
Koga S; Nishikido M; Matsuya F; Kanetake H; Saito Y
Anticancer Res; 1999; 19(6C):5547-50. PubMed ID: 10697614
[TBL] [Abstract][Full Text] [Related]
5. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and the role of nephrectomy in metastatic renal cell carcinoma.
Uygur MC; Usubütün A; Ozen H; Ayhan A; Kendi S
J Exp Clin Cancer Res; 1999 Sep; 18(3):397-401. PubMed ID: 10606187
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
8. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
[TBL] [Abstract][Full Text] [Related]
10. [Survival analysis of interferon-alpha on locally advanced clear cell renal cell carcinoma after radical nephrectomy].
Xia J; Li X; Chen XQ; Li X; Zeng H; Wei Q; Zhang P; Zhu YC
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):91-4. PubMed ID: 22455140
[TBL] [Abstract][Full Text] [Related]
11. Multi-cytokine therapy for advanced renal cell carcinoma: determination of the minimal effective dose.
Hamada I; Kato M; Okada K
Anticancer Res; 2002; 22(4):2429-36. PubMed ID: 12174939
[TBL] [Abstract][Full Text] [Related]
12. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
Négrier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
[TBL] [Abstract][Full Text] [Related]
13. Interferon in metastatic renal cell carcinoma.
Fosså SD
Semin Oncol; 2000 Apr; 27(2):187-93. PubMed ID: 10768597
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma.
Obara W; Mizutani Y; Oyama C; Akaza H; Ishii N; Kohri K; Namiki M; Okuyama A; Shima H; Yokoyama M; Shuin T; Miki T; Watanabe Y; Fujioka T
Int J Urol; 2008 Sep; 15(9):794-9. PubMed ID: 18651865
[TBL] [Abstract][Full Text] [Related]
15. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Dunlap S; Elchinoff A; Yu N; Bok R; Simko J; Small EJ
Cancer; 2006 Feb; 106(3):566-75. PubMed ID: 16369983
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil number after interferon-alfa treatment is an independent predictive marker of overall survival in metastatic renal cell carcinoma.
Azuma T; Matayoshi Y; Nagase Y; Oshi M
Clin Genitourin Cancer; 2012 Sep; 10(3):180-4. PubMed ID: 22608529
[TBL] [Abstract][Full Text] [Related]
17. [Interferon-based cytokine therapy for advanced renal cell carcinoma].
Takayama T; Kai F; Sugiyama T; Furuse H; Mugiya S; Ozono S
Hinyokika Kiyo; 2005 Aug; 51(8):499-502. PubMed ID: 16164263
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of adjuvant interferon-alpha therapy following curative resection in renal cell carcinoma: before the molecular targeting therapy era.
Kai F; Takayama T; Sugiyama T; Furuse H; Mugiya S; Ozono S
Jpn J Clin Oncol; 2009 May; 39(5):310-4. PubMed ID: 19363055
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
